title: Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study.
abstract: BACKGROUND
  Recent studies have demonstrated that pathological analysis of retroperitoneal residual masses of patients with testicular germ cell tumors revealed findings of necrotic debris or fibrosis in up to 50% of patients. We aimed at pursuing a clinical and pathological review of patients undergoing post chemotherapy retroperitoneal lymph node dissection (PC-RPLND) in order to identify variables that may help predict necrosis in the retroperitoneum.
  
  
  METHODS
  We performed a retrospective analysis of all patients who underwent PC-RPLND at the University Hospital of the University of São Paulo and Cancer Institute of Sao Paulo between January 2005 and September 2011. Clinical and pathological data were obtained and consisted basically of: measures of retroperitoneal masses, histology of the orchiectomy specimen, serum tumor marker and retroperitoneal nodal size before and after chemotherapy.
  
  
  RESULTS
  We gathered a total of 32 patients with a mean age of 29.7; pathological analysis in our series demonstrated that 15 (47%) had necrosis in residual retroperitoneal masses, 15 had teratoma (47%) and 2 (6.4%) had viable germ cell tumors (GCT). The mean size of the retroperitoneal mass was 4.94 cm in our sample, without a difference between the groups (P = 0.176). From all studied variables, relative changes in retroperitoneal lymph node size (P = 0.04), the absence of teratoma in the orchiectomy specimen (P = 0.03) and the presence of choriocarcinoma in the testicular analysis after orchiectomy (P = 0.03) were statistically significant predictors of the presence of necrosis. A reduction level of 35% was therefore suggested to be the best cutoff for predicting the absence of tumor in the retroperitoneum with a sensitivity of 73.3% and specificity of 82.4%.
  
  
  CONCLUSIONS
  Even though retroperitoneal lymph node dissection remains the gold standard for patients with residual masses, those without teratoma in the primary tumor and a shrinkage of 35% or more in retroperitoneal mass have a considerably smaller chance of having viable GCT or teratoma in the retroperitoneum and a surveillance program could be considered.
authors.affiliation: Division of Urology, University of Sao Paulo Medical School and Cancer Institute of Sao Paulo, ICESP, São Paulo, SP, Brazil.
authors.forename: Eduardo de Paula
authors.initials: Ede P
authors.lastname: Miranda
authors.forename: Daniel Kanda
authors.initials: DK
authors.lastname: Abe
authors.forename: Adriano João
authors.initials: AJ
authors.lastname: Nesrallah
authors.forename: Sabrina Thalita
authors.initials: ST
authors.lastname: dos Reis
authors.forename: Alexandre
authors.initials: A
authors.lastname: Crippa
authors.forename: Miguel
authors.initials: M
authors.lastname: Srougi
authors.forename: Marcos Francisco
authors.initials: MF
authors.lastname: Dall'Oglio
mesh_terms: D000293:Adolescent; D000328:Adult; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D009373:Neoplasms, Germ Cell and Embryonal / Q000473:pathology; D012186:Retroperitoneal Neoplasms / Q000473:pathology*; D012189:Retrospective Studies; D013724:Teratoma / Q000473:pathology; D013736:Testicular Neoplasms / Q000473:pathology*